Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.

par Shunsuke Tsuzuki, Shotaro Nakanishi, Mitsuyoshi Tamaki, Takuma Oshiro, Jun Miki, Hiroki Yamada, Tatsuya Shimomura, Takahiro Kimura, Nozomu Furuta, Seiichi Saito, Shin Egawa
Publié 2021

12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population

par Ryo Takata, Atsushi Takahashi, Masashi Fujita, Yukihide Momozawa, Edward J. Saunders, Hiroki Yamada, Kazuhiro Maejima, Kaoru Nakano, Yuichiro Nishida, Asahi Hishida, Keitaro Matsuo, Kenji Wakai, Taiki Yamaji, Norie Sawada, Motoki Iwasaki, Shoichiro Tsugane, Makoto Sasaki, Atsushi Shimizu, Kozo Tanno, Naoko Minegishi, Kichiya Suzuki, Koichi Matsuda, Michiaki Kubo, Johji Inazawa, Shin Egawa, Christopher A. Haiman, Osamu Ogawa, Wataru Obara, Yoichiro Kamatani, Shusuke Akamatsu, Hidewaki Nakagawa
Publié 2019